HRP20160995T1 - Cjepivo fuzijskog proteina - Google Patents

Cjepivo fuzijskog proteina Download PDF

Info

Publication number
HRP20160995T1
HRP20160995T1 HRP20160995TT HRP20160995T HRP20160995T1 HR P20160995 T1 HRP20160995 T1 HR P20160995T1 HR P20160995T T HRP20160995T T HR P20160995TT HR P20160995 T HRP20160995 T HR P20160995T HR P20160995 T1 HRP20160995 T1 HR P20160995T1
Authority
HR
Croatia
Prior art keywords
amino acid
fusion protein
acid sequence
seq
identity
Prior art date
Application number
HRP20160995TT
Other languages
English (en)
Inventor
Gunnar Lindahl
Original Assignee
Minervax Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minervax Aps filed Critical Minervax Aps
Publication of HRP20160995T1 publication Critical patent/HRP20160995T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (12)

1. Fuzijski protein sadrži najmanje dva slijeda aminokiselina, pri čemu se navedena dva slijeda aminokiselina sastoje od prvog slijeda aminokiselina koji ima najmanje 90% identičnosti slijeda sa slijedom aminokiselina prikazanim u SEQ ID NO:2, spojenim na drugi slijed aminokiselina koji ima najmanje 90% identičnosti slijeda sa slijedom aminokiselina prikazanim u SEQ ID NO:4, pri čemu je navedeni fuzijski protein sposoban potaknuti zaštitni imunitet prema Streptococcusu grupe B.
2. Fuzijski protein u skladu s patentnim zahtjevom 1, pri čemu navedeni prvi slijed aminokiselina ima najmanje 95, 96, 97, 98 ili 99% identičnosti slijeda sa slijedom aminokiselina prikazanim u SQE ID NO:2 ili pri čemu navedeni drugi slijed aminokiselina ima najmanje 95, 96, 97, 98 ili 99% identičnosti slijeda sa slijedom aminokiselina prikazanim u SQE ID NO:4.
3. Fuzijski protein u skladu s patentnim zahtjevom 1, pri čemu fuzijski protein obuhvaća slijed aminokiselina koji ima najmanje 90% identičnosti sa slijedom aminokiselina prikazanim u SEQ ID NO:6.
4. Fuzijski protein u skladu s patentnim zahtjevom 3, pri čemu fuzijski protein obuhvaća slijed aminokiselina koji ima najmanje 95% identičnosti sa slijedom aminokiselina prikazanim u SEQ ID NO:6.
5. Fuzijski protein u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu je navedeni fuzijski protein modificiran glikozilacijom, amidacijom, karboksilacijom ili fosforilacijom.
6. Cjepivo koje sadrži farmaceutski učinkovitu količinu fuzijskog proteina u skladu s bilo kojim od patentnih zahtjeva 1-5, pri čemu navedeni sastav cjepiva sposoban potaknuti zaštitni imunitet prema Streptococcusu grupe B sadrži farmaceutski prihvatljivi nosač.
7. Cjepivo u skladu s patentnim zahtjevom 6, koje nadalje sadrži adjuvans.
8. Cjepivo u skladu s bilo kojim od patentnih zahtjeva 6-7, pri čemu je navedeni fuzijski protein konjugiran s polisaharidom zbog stvaranja konjugata cjepiva.
9. Slijed nukleotida koji obuhvaća najmanje slijed nukleotida SEQ ID NO:1 udružen sa SEQ ID NO:3 ili slijed nukleotida prikazan u SEQ ID NO:5.
10. Slijed nukleotida u skladu s patentnim zahtjevom 9, pri čemu su SEQ ID NO:1 i 3 kemijski povezani, konjugirani ili umreženi.
11. Vektor koji sadrži slijed nukleotida u skladu s patentnim zahtjevom 9-10.
12. Stanica domaćin sadrži vektor u skladu s patentnim zahtjevom 11.
HRP20160995TT 2007-04-16 2016-08-08 Cjepivo fuzijskog proteina HRP20160995T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0700919 2007-04-16
US94047307P 2007-05-29 2007-05-29
PCT/SE2008/000270 WO2008127179A1 (en) 2007-04-16 2008-04-14 Fusion protein vaccine
EP08724181.6A EP2144924B1 (en) 2007-04-16 2008-04-14 Fusion protein vaccine

Publications (1)

Publication Number Publication Date
HRP20160995T1 true HRP20160995T1 (hr) 2016-10-21

Family

ID=39864173

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160995TT HRP20160995T1 (hr) 2007-04-16 2016-08-08 Cjepivo fuzijskog proteina

Country Status (15)

Country Link
US (1) US8313748B2 (hr)
EP (1) EP2144924B1 (hr)
CN (1) CN101855238B (hr)
CA (1) CA2684494C (hr)
CY (1) CY1117896T1 (hr)
DK (1) DK2144924T3 (hr)
ES (1) ES2586418T3 (hr)
HR (1) HRP20160995T1 (hr)
HU (1) HUE028253T2 (hr)
LT (1) LT2144924T (hr)
PL (1) PL2144924T3 (hr)
PT (1) PT2144924T (hr)
RU (1) RU2487890C2 (hr)
SI (1) SI2144924T1 (hr)
WO (1) WO2008127179A1 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
RU2015106791A (ru) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
CN103694323B (zh) * 2013-12-09 2017-01-18 成都欧林生物科技股份有限公司 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用
WO2017068112A1 (en) * 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
CA3004631A1 (en) * 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021250625A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein
CN114437235B (zh) * 2022-01-04 2024-02-09 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 马链球菌马亚种8种蛋白的重组融合蛋白及其制备方法和应用
CN116478953B (zh) * 2023-06-14 2023-09-12 四川大学华西医院 鲍曼不动杆菌DlaT重组蛋白、制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225579A (en) * 1979-02-27 1980-09-30 Israel Kleinberg Means and method for improving defenses against caries
US4496538A (en) 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
WO1994001031A1 (fr) 1992-07-02 1994-01-20 Paul Charvet Appareil de cuisson dans l'huile a chauffage au gaz
IL107025A0 (en) 1992-09-16 1993-12-28 Univ Tennessee Res Corp Recombinant multivalent m protein vaccine
IL107458A0 (en) 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
KR100331358B1 (ko) 1993-03-19 2002-08-13 구나르린달 그룹B스트렙토코커스의많은균주들에대한면역성을제공하는세포표면단백질인Rib단백질,그단백질의정제방법,시약키트및제약조성물
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
ES2295836T3 (es) * 2003-03-13 2008-04-16 Glaxosmithkline Biologicals S.A. Procedimiento de purificacion de citolisina bacteriana.
CA2537742C (en) 2003-09-15 2014-07-22 Chiron Corporation Immunogenic compositions for streptococcus agalactiae

Also Published As

Publication number Publication date
RU2009142976A (ru) 2011-05-27
CY1117896T1 (el) 2017-05-17
CN101855238B (zh) 2014-09-17
DK2144924T3 (en) 2016-08-22
CA2684494A1 (en) 2008-10-23
CA2684494C (en) 2016-07-05
LT2144924T (lt) 2016-10-10
RU2487890C2 (ru) 2013-07-20
SI2144924T1 (sl) 2016-12-30
EP2144924B1 (en) 2016-05-11
CN101855238A (zh) 2010-10-06
WO2008127179A8 (en) 2009-07-23
US8313748B2 (en) 2012-11-20
PT2144924T (pt) 2016-08-17
PL2144924T3 (pl) 2017-06-30
WO2008127179A1 (en) 2008-10-23
HUE028253T2 (en) 2017-02-28
US20100062015A1 (en) 2010-03-11
EP2144924A4 (en) 2010-08-25
ES2586418T3 (es) 2016-10-14
EP2144924A1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
HRP20160995T1 (hr) Cjepivo fuzijskog proteina
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2013507132A5 (hr)
HRP20170530T1 (hr) Modulacija aktivnosti proneutrofina
JP2013172734A5 (hr)
WO2007048086A3 (en) Canine influenza virus and related compositions and methods of use
HRP20240042T1 (hr) Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci
RS52535B (en) PHARMACEUTICAL MIXTURES CONTAINING ACTIVIN-ACTRIIA ANTAGONISTS AND THEIR USE IN THE PREVENTION OR TREATMENT OF MULTIPLE MYELOMA
RS50966B (sr) Agonisti pyy i njihova upotreba
HRP20240226T1 (hr) Pripravci cjepiva koji sadrže protein vezivanja mutiranog faktora h
HRP20230761T1 (hr) Gdf zamke
WO2007091030A3 (en) Peptide sequences and compositions
RS54204B1 (en) NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR
HRP20220070T1 (hr) Cjepiva nukleinske kiseline
PE20090711A1 (es) Region constante de anticuerpo mutante
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
WO2007048857A8 (es) USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE
WO2009025117A1 (ja) Cdca1ペプチド及びこれを含む薬剤
ES2570760T3 (es) Biogel
JP2008521795A5 (hr)
NZ601345A (en) Combination adjuvant formulation
RU2018116601A (ru) Иммунногенный слитый белок
BR112012021269A2 (pt) composição modular.
JP2003533186A5 (hr)
WO2016115511A3 (en) Vegf variant polypeptide compositions